For example, in another case–control study, the same tri-allelic polymorphism, genotyped in 1164 BC patients and compared to 1701 cancer-free controls, was associated with BC risk, especially for the luminal-like subtype but not with HER2-positive or triple-negative subtypes [76]. This evidence concerns the gene ERBB2 and breast cancer.